The estimated Net Worth of Paul K Wotton is at least $1.97 Milión dollars as of 1 May 2024. Paul Wotton owns over 3,200 units of Vericel Corp stock worth over $1,311,087 and over the last 12 years he sold VCEL stock worth over $439,150. In addition, he makes $218,085 as Independent Director at Vericel Corp.
Sign up
Paul Wotton VCEL stock SEC Form 4 insiders trading
Paul has made over 20 trades of the Vericel Corp stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 3,200 units of VCEL stock worth $139,840 on 1 May 2024.
The largest trade he's ever made was exercising 125,000 units of Vericel Corp stock on 3 June 2013 worth over $62,500. On average, Paul trades about 17,102 units every 134 days since 2012. As of 1 May 2024 he still owns at least 30,002 units of Vericel Corp stock.
You can see the complete history of Paul Wotton stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Paul Wotton biography
Dr. Paul Kevin Wotton is an Independent Director of the company. Dr. Wotton is a director since January 2015, currently serves on the board of directors and is the Chief Executive Officer of Obsidian Therapeutics, Inc, a position he has held since April 2019. Previously, he was the founding President and Chief Executive Officer of Sigilon Therapeutics, Inc., a privately-held cell therapeutics company started in May 2016. Prior to that, he served as the President and Chief Executive Officer and as a member of the board of directors of Ocata Therapeutics, Inc. from July 2014, until its acquisition by Astellas Pharma US, Inc. in February 2016, where he also served as the Co-Chairman of the Integration Management Office from February 2016 until May 2016. Prior to Ocata, Dr. Wotton served as President and Chief Executive Officer and as a member of the board of directors of Antares Pharma, Inc. from October 2008 to June 2014. Prior to joining Antares, Dr. Wotton was the Chief Executive Officer of Topigen Pharmaceuticals. Prior to Topigen, he was the Global Head of Business Development of SkyePharma PLC. Earlier in his career, Dr. Wotton held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr. Wotton serves as Chairman of the board of directors of Cynata Therapeutics Limited and, previously, was a member of the board of directors and Chairman of the compensation committee of Veloxis Pharmaceuticals A/S, until its acquisition by Asahi Kasei in January 2020. Dr. Wotton is also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada. In 2014, Dr. Wotton was named Ernst & Young Entrepreneur of the Year for Life Sciences, New Jersey. Dr. Wotton received his Bachelor's in Pharmacy, with honors, from University College London, his Ph.D. in pharmaceutical sciences from the University of Nottingham and his MBA from Kingston Business School.
What is the salary of Paul Wotton?
As the Independent Director of Vericel Corp, the total compensation of Paul Wotton at Vericel Corp is $218,085. There are 12 executives at Vericel Corp getting paid more, with Dominick Colangelo having the highest compensation of $5,385,530.
How old is Paul Wotton?
Paul Wotton is 59, he's been the Independent Director of Vericel Corp since 2017. There are 5 older and 7 younger executives at Vericel Corp. The oldest executive at Vericel Corp is Robert Zerbe, 69, who is the Independent Chairman of the Board.
What's Paul Wotton's mailing address?
Paul's mailing address filed with the SEC is C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Insiders trading at Vericel Corp
Over the last 10 years, insiders at Vericel Corp have traded over $9,831,645 worth of Vericel Corp stock and bought 890 units worth $10,297 . The most active insiders traders include Dominick Colangelo, Gerard J Michel a Kevin F Mclaughlin. On average, Vericel Corp executives and independent directors trade stock every 17 days with the average trade being worth of $567,401. The most recent stock trade was executed by Steven C Gilman on 4 September 2024, trading 5,000 units of VCEL stock currently worth $18,700.
What does Vericel Corp do?
about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea
What does Vericel Corp's logo look like?
Complete history of Paul Wotton stock trades at Antares Pharma Inc a Vericel Corp
Vericel Corp executives and stock owners
Vericel Corp executives and other stock owners filed with the SEC include:
-
Dominick Colangelo,
President, Chief Executive Officer, Director -
Michael Halpin,
Chief Operating Officer -
Dominick C. Colangelo Esq.,
CEO, Pres & Director -
Michael Halpin,
Chief Operating Officer -
Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B.,
Chief Medical Officer -
Dr. Jonathan M. Hopper,
Chief Medical Officer -
Sean C. Flynn,
VP, Gen. Counsel & Sec. -
Robert Zerbe,
Independent Chairman of the Board -
Alan Rubino,
Independent Director -
Kevin McLaughlin,
Independent Director -
Heidi Hagen,
Independent Director -
Steven Gilman,
Independent Director -
Paul Wotton,
Independent Director -
Sandra Pennell,
Principal Financial Officer and Principal Accounting Officer -
Jonathan Siegal,
Principal Accounting Officer, VP & Corp. Controller -
Roland DeAngelis,
Sr. VP of Commercial Operations -
Heidi Hassen,
VP of HR -
Patrick J. Fowler,
Sr. VP of Corp. Devel. & Strategy -
Eric Burns,
Exec. Director of Financial Planning and Analysis & Investor Relations -
Joseph Anthony Mara Jr.,
CFO, Principal Accounting Officer & Treasurer -
Capital Management Lp Conso...,
-
Daniel Orlando,
Chief Operating Officer -
Gerard J Michel,
CFO and VP, Corp. Development -
Nelson M Sims,
Director -
Lisa Wright,
-
Joseph Anthony Jr Mara,
Chief Financial Officer -
Jonathan Siegal,
Principal Accounting Officer -
Jonathan Mark Hopper,
Chief Medical Officer -
Sean C. Flynn,
Chief Legal Officer